HEPP News, Vol. 2 No. 11 by HIV Education Prison Project
University of Rhode Island
DigitalCommons@URI
Infectious Diseases in Corrections Report (IDCR)
1999
HEPP News, Vol. 2 No. 11
HIV Education Prison Project
Follow this and additional works at: http://digitalcommons.uri.edu/idcr
This Article is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Infectious Diseases in
Corrections Report (IDCR) by an authorized administrator of DigitalCommons@URI. For more information, please contact
digitalcommons@etal.uri.edu.
Recommended Citation
HIV Education Prison Project, "HEPP News, Vol. 2 No. 11" (1999). Infectious Diseases in Corrections Report (IDCR). Paper 10.
http://digitalcommons.uri.edu/idcr/10
A b o u t  H e p p
HEPP News, a forum for correctional
problem solving, targets correctional
administrators and HIV/AIDS care
providers including physicians, nurses,
outreach workers, and case managers.
Published monthly and distributed by fax,
HEPP News provides up-to-the-moment
information on HIV treatment, efficient
approaches to administering HIV treatment
in the correctional environment, national
and international news related to HIV in
prisons and jails, and changes in correc-
tional care that impact HIV treatment.
Continuing Medical Education credits are
provided by the Brown University Office of
Continuing Medical Education to physi-
cians who accurately respond to the ques-
tions on the last page of the newsletter.  
The editorial board and contributors to
HEPP News include national and regional
correctional professionals, selected on the
basis of their experience with HIV care in
the correctional setting and their familiarity
with current HIV treatment. We encourage
submissions, feedback, and correspon-
dence from our readership.  The goal of
HEPP News is to provide our readers with
reports of effective and cost-conscious HIV
care that can truly be implemented with the
correctional environment.  We hope our
newsletter achieves that goal.
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Prevention and Treatment of HIV/AIDS and Other Infectious 
Diseases in Correctional Settings: An Opportunity Not Yet Seized
Theodore M. Hammett, Ph.D.
Abt Associates Inc.
Correctional health care providers manage
the care of a large number of individuals with
communicable diseases in the U.S. A major
portion of the nations Hepatitis B&C, HIV,
STD and TB infected patients pass through
prison and jail doors (see Heppigram).
Moreover, many of these individuals also have
other co-morbid conditions such as psychiatric
illnesses, substance abuse and chronic med-
ical conditions that thwart an integrated care
approach for these patients in community set-
tings.
Within correctional populations, moreover,
women and people of color are much more
heavily affected than men and Caucasian
inmates.  For instance, in most geographical
areas, the prevalence of HIV among women
prisoners is twice that found among male pris-
oners.  Similar to findings in community-
derived studies, people of color are dispropor-
tionately affected by all communicable dis-
eases, however this phenomenon is magni-
fied within our correctional system.
The disproportionately high burden of disease
in correctional institutions identifies an
extremely important opportunity to intervene
aggressively with prevention and treatment
programs.  Such interventions promise to ben-
efit not only inmates themselves and their
partners and families, but also the broader
public health. Contrary to popular perception,
correctional facilities are a part of the commu-
nity. The vast majority of inmates return to our
streets and neighborhoods --more than 8 mil-
lion are released from jails and prisons per
year -- where they may either continue to
place themselves and others at risk for infec-
tious disease, or help to halt the linked epi-
demics of disease in the poor, under-served
communities which are home to most of them.  
The nation’s correctional systems, public
health departments, and community based
providers have not yet exploited this important
public health opportunity, except in a minority
of instances. While there have been improve-
ments in recent years and many correctional
administrators appear to be taking an increas-
ingly enlightened view of health services and
disease prevention, there remains consider-
able room for improvement. Results of a
series of national surveys of HIV/AIDS, STDs,
and TB in correctional facilities elucidate the
key areas of need.1 Progress and remaining
needs in several key areas are summarized
below.
Substance abuse treatment
The vast majority of correctional inmates have
substance abuse problems. Successful treat-
ment and achievement of permanent sobriety
normally require multiple and prolonged treat-
ment episodes. Periods of incarceration offer
important opportunities to provide substance
abuse treatment and thereby increase ex-
offenders’ chances of resisting relapse and
avoiding recidivism.
Nevertheless, statistics from the Center on
Addiction and Substance Abuse (CASA) at
Columbia University reveal a serious and
growing gap between the number of inmates
needing drug treatment and those receiving
treatment. In 1996, CASA estimated, there
were 840,000 inmates in need of treatment
but only 150,000 (18%) in treatment in correc-
tional facilities.2 Current drug treatment pro-
grams are rarely offered to individuals in jails
or who are serving short sentences. 
Treatment for HIV Disease
The 1996-1997 CDC/NIJ survey was conduct-
ed just as the new antiretroviral therapies
were becoming widely available. The survey
included only a limited number of questions
about HIV treatment.  The next round of the
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survey will examine treatment in greater
detail. The responses to these questions
indicate that the vast majority of state/feder-
al and city/county correctional systems
made protease inhibitors (90%, 93%) and
combination therapy (90%, 90%) available to
inmates. However, these results do not
demonstrate that these therapies were pro-
vided to all inmates who should have been
receiving them on an uninterrupted basis.
Indeed, there is anecdotal evidence to sug-
gest that there may be substantial problems
with continuously available medications in at
least some correctional facilities. Nor do the
survey results demonstrate that inmates
were being prescribed the most appropriate
combination therapies. A recent study by
Stadtlanders Pharmacy, which provides
pharmacy services to many correctional sys-
tems, found that 52% of about 3,500 inmates
whose pharmacy records were examined
were receiving either "preferred" (45%) or
"alternative" (7%) combinations based on
currently accepted federal guidelines and
more than one third were receiving either
"not generally recommended’ (28%) or "not
recommended" (8%) regimens.3 There is
clearly room for improvement in compliance
with the DHHS Guidelines in treating HIV-
infected inmates.
HIV/AIDS education and prevention
As of 1997, about two-thirds of correctional
facilities in the U.S. were providing instruc-
tor-led HIV/AIDS education, the most basic
ingredient of an education and prevention
program. Moreover, while most HIV educa-
tion programs covered basic information on
the disease, far fewer included practical risk
reduction information, such as strategies for
negotiating safer sex and methods of safer
injection. Only about a third were providing
more intensive multi-session HIV prevention
counseling programs, the type of program
probably needed to help inmates initiate and
sustain the difficult behavioral changes
required to reduce their risks of acquiring or
transmitting HIV and other infectious dis-
eases. Finally, only 13% of prisons and 3%
of jails were offering peer-based programs in
which inmates provide education and pre-
vention services to other inmates. This rep-
resents an extremely under utilized but
promising and potentially very cost-effective 
method of providing these services. 
One definition of a "comprehensive"
HIV/AIDS education and prevention program
is that all of the following are provided in all
of a correctional system’s facilities: instruc-
tor-led education; HIV pre- and post-test
counseling; peer-led programs; and multi-
session prevention counseling. By this defin-
ition, only 10% of state and federal prison
systems and only 5% of the 50 largest jail
systems in the U.S. had a comprehensive
program in 1997. 
Beyond this, some may consider a "comprehen-
sive" program to include provision of the means
necessary to effectuate HIV risk reduction.
Perhaps the most commonly advocated such pol-
icy is making condoms available to inmates.
However, political considerations have made it
extremely difficult for correctional administrators to
permit condom distribution even though it is hard to
deny that inmates engage in sexual activity within
correctional facilities. As a consequence, only two
state prison systems (Vermont and Mississippi)
and four city/county jail systems (District of
Columbia, New York City, Philadelphia, and San
Francisco) make condoms available to inmates.
This number has not changed since about 1990.
Discharge planning /community linkages
All inmates need more and better services to
help them make successful transitions to the
community, resist relapse to substance use,
and avoid a return to high-risk behavior and
criminal activity. This is especially true for
inmates with HIV disease, who might benefit
from a range of services including continuity
of health care, stable housing, drug treat-
ment, assistance gaining eligibility for bene-
fits, and job training and placement services.
Results of the 1996-1997 CDC/NIJ survey
show that 92% of state/federal prison sys-
tems and 76% of the largest city/county jail
systems were providing at least some dis-
charge planning for inmates with HIV and
AIDS. However, further analysis of the sur-
vey data reveals that while large percent-
ages of systems were making referrals for
HIV medications (82% of state/federal sys-
tems and 66% of city/county systems), drug
treatment (75% and 63%), and for Medicaid
and related benefits (78%, 56%), much 
smaller percentages were actually making
appointments for inmates to receive these
services in the community (31% of state/fed
eral systems and 27% of city/county systems
for HIV medications, 22% and 24% for drug
treatment, and 35% and 29% for benefits).
Making a referral can involve simply giving
an individual a list of agencies where they
might apply for services with no further
assistance in actually accessing the ser-
vices. Making an appointment for a soon-to-
be-released inmate with a specific service
provider by no means guarantees that the
person will show up and receive the ser-
vices, but it represents an additional step in
the process. Geography can be a significant
obstacle to achieving a successful transition.
Exemplary programs in small geographic
locations in Rhode Island4 and Hampden
County, Massachusetts5 successfully pro-
vide continuity of services by having local
clinicians provide care both within and out-
side of the correctional facility.  Successful
models in moderate-sized geographic areas,
such as in Connecticut,6 have adopted a
transitional case management model to
overcome problems associated with geogra-
phy. Such programs are beginning to
demonstrate salutary effects on clinical out-
comes as well as on recidivism rates of
inmates participating in them.
Collaboration needed 
Correctional systems cannot be expected to
take full responsibility for addressing the
serious public health problem or exploiting
the important public health opportunity rep-
resented by the related epidemics of infec-
tious diseases in correctional facilities.
Public health departments, community-
based organizations such as AIDS service
organizations and community-based sub-
stance abuse treatment agencies, and other
community-based providers have critical
roles to play as well. There is increasing col-
laboration among these entities, but there
remain far more opportunities and needs for
working together.  There are differences in
philosophy and priority among these organi-
zations, to be sure, but there are also grow-
ing examples of overcoming the barriers and
forging successful collaborations to provide
needed services to inmates and releasees
as well as to benefit the public health and
serve the interests of society at large.7
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L E T T E R F R O M T H E E D I T O R
Dear Readers,
This issue of HEPP News marks the last issue of the Millennium!  I can think of no better way to end it than to
emphasize the important work presented by Drs. Hammett and Greifinger on the extent of co-morbid medical con-
ditions housed within the U.S. correctional system.  This month’s HeppiGram depicts some of the information pro-
vided.  Dr. Hammett reviews for us the burden of HIV and the extent to which current correctional systems have
succeeded in developing comprehensive programs to diagnose, treat and prevent communicable diseases within
our walls.  
An interview with Dr. Greifinger and the data he presented at the recent NCCHC meeting in Ft. Lauderdale, FL,
provides insight into the burden of other co-morbid conditions, namely chronic diseases and psychiatric illness.
These data likely represent the minimum burden of disease within the US correctional system as standardized
screening methods were not used to compile the data at selected reporting sites.  My hope for these data, which
are to be presented to Congress, is to prompt the federal government to into a more proactive stance in integrat-
ing correctional health with our public health system.
Dr. Augustine Mekkum provided an unsolicited opinion piece discussing adherence strategies within correctional
systems. This is one of the most thoughtful pieces on adherence in correctional facilities I’ve reviewed. However it
is important to recognize that one system does not work for all inmates just as one antiretroviral combination does
not - the operative word is individualize!  The unruly nature of medication lines (outside conditions, long lines, poor
confidentiality, etc.) may make "keep on person" the best alternative in some correctional settings.  Moreover, are
there not other viable alternatives such as DOT until a person learns how to properly take the medications, is
beyond the initial side effects and has achieved a non-detectable viral load? 
Other features this month include graphics showing the prevalence of infectious disease in corrections and antivi-
ral drug interactions.  After reviewing this issue, readers should be able to list in order of prevalence which infec-
tious diseases are seen most frequently in correctional systems, describe the burden of mental health disorders,
and identify appropriate antiviral combinations.  In next month’s issue, we’ll bring you Newton Kendig’s discussion
of public health and corrections collaborations, as well as a summary of the latest HIV treatment guidelines.
The end of the Millennium (the year for most of us) marks a time for major resolutions.  I believe I can speak for
Anne and and new editor Joe Bick by saying that our resolution for the next Millennium is to keep our Newsletter
up-to-date, clearly written, and arriving on time. Our mission for next year is to go international - watch for updates
from Europe, Australia, and the United Kingdom! The entire staff at HEPP News wishes each of you a prosperous
New Year and New Millennium!
Rick Altice, M.D.
Asst. Professor of Medicine
Director, HIV in Prisons Program
Yale University AIDS Program
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Robert Greifinger, MD, is a correctional health care consultant and former
chief medical officer for the New York State Department of Correctional
Services. One of Dr. Greifinger’s many projects has been to coordinate an
evaluation of the health status of prison and jail inmates for the National
Commission on Correctional Health Care (NCCHC) that was funded by
the NCCHC and the National Institute of Justice (NIJ). The complete
report will be presented to the U.S. Congress in early 2000. Dr. Greifinger
provided HEPP News and an eager audience of correctional health care
providers with a glimpse of the report’s findings during his presentation at
the NCCHC in Ft. Lauderdale, FL and during a recent interview.
The goal of this project was to estimate the burden of disease among
soon-to-be-released incarcerated individuals and to make recommenda-
tions for public health interventions. The report will provide suggestions to
the federal government for improvements in health care management
within correctional systems.
The report underscores a problem with which correctional providers
should already be familiar: correctional facilities are coping with patients
who have many undiagnosed and untreated health problems and who
have had little access to health care prior to incarceration. Improved man-
agement of the many health conditions afflicting inmates will have a dra-
matic impact on the health care needs of the communities to which they
return. Therefore, Dr. Greifinger feels that the health status of soon-to-be-
released inmates is an important component of the community’s health
and deserves to be a targeted public health intervention.
The Extent of the Problem 
Dr. Griefinger provided correctional system-reported prevalence projec-
tions of various diseases in corrections based on existing survey data.1
Dr. Greifinger emphasizes the fact that these data are projections, and not
based on actual surveys. Data were adjusted for the socioeconomic and
demographic characteristics of inmates. He provided information on the
burden of disease in three categories: communicable diseases, mental
health conditions, and chronic illnesses.
Communicable Disease
Communicable diseases of greatest significance to correctional HIV
providers include Hepatitis B and C, HIV, sexually transmitted infections
(syphilis, gonorrhea, and chlamydia) and airborne diseases such as tuber-
culosis 
Table 1.  Communicable Diseases
Key:
*Personal communication, Robert Greifinger, December 1999. Percentages cal-
culated by HEPP staff using the reported numbers divided by 8 million, the
approximate number of total annual releases.
**Hammett TM, Harmon P, Rhodes W.  The Burden of Infectious Disease Among
Inmates and Releasees from Correctional Facilities. Prepared for the National
Commission on Correctional Health Care-National Institute of Justice "Health
Status of Soon-to-be-Released Inmates" Project, presented at the National
Commission on Correctional Health Care Conference in Fort Lauderdale, FL,
1999. 
^These numbers were qualified in Hammett’s study as follows: "The large range
in these numbers reflect the fact that their data are based on a combination of test-
ing methodologies which may have different sensitivities. Moreover, sex workers
and others likely at highest risk for STDs may be disproportionately represented
among those released without having been screened.  Thus, statistics on jail
intake screening for STDs probably understate the true prevalence of STDs
among people passing through jails."
^^According to Hammett’s study, there are no reliable data on the total US preva-
lence of these three diseases.  Thus we did not attempt to calculate these per-
centages.
Mental Illness
The prevalence of major psychiatric disorders was 50% higher among
incarcerated populations than in the community. However, some mental
illnesses are still under reported in correctional settings. For example,
under-diagnosed or undiagnosed conditions uncovered by this report
included schizophrenia, major depression, and bipolar disorders. The
prevalence of known mental health disorders among inmates currently in
custody is shown in Table 2. 
Table 2. Prevalence of Severe Mental illness in Jails and Prisions*
*Personal Communication, Robert Greifinger, December 1999
Compounding the problem, a high percentage of inmates with mental ill-
ness also have a co-occurring substance abuse problem.  Dr. Greifinger
recommended that correctional providers become familiar with the treat-
ment of patients who carry a "dual diagnosis" (mental illness and sub-
stance abuse), the group at highest risk for recidivism.
Chronic diseases
Dr. Greifinger’s project also reported on the prevalence of asthma, hyper-
tension and diabetes (see Table 3) among inmates. He said these figures
should cause correctional health providers and policy makers as well as
public health planners to recognize that these conditions are highly preva-
lent in correctional settings. 
Table 3. Prevalence of Chronic Diseases in Prisons and Jails*
*Percentages derived from Greifinger’s reported numbers divided by the
number of jail and prison inmates as reported in the Bureau of Justice
Statistics Bulletine, Prison and Jail Inmates at Midyear 1995.  August
1996, NCJ 161132.
The Recommendations
While the projections may be eye-opening to many, Dr. Greifinger and his
colleagues hope that the report will be a catalyst for changes in correc-
tional health care.  He anticipates that the report will make a number of
recommendations to Congress. For example, he suggested that
Congress will need to improve surveillance of communicable diseases,
mental illness and chronic disease in correctional settings. He believes
the report will indicate that Congress should fund a program to develop
the standards for measurement and reporting mechanisms for these dis-
eases. The data might be housed in a national clearinghouse or database,
similar to the HEDIS database for managed care.  Dr. Greifinger also sug-
gested that clinical guidelines for prisons and jails may need to be devel-
oped to reflect nationally accepted, evidenced based guidelines and have
a measurement of performance against those guidelines. One example
would be to use the National Institutes of Health treatment guidelines for
HIV. In addition, correctional and public health professionals might be
required to become familiar with the guidelines. He thought that the report
would also suggest that a resource be developed to provide correctional
healthcare professionals to updated treatment protocols. Ideally this data-
base would be available on the Internet. 
Dr. Greifinger also reported that the following recommendations would be
featured in the report to Congress:
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Spotlight:  Revealing the Need for Change: An Interview with Robert Greifinger, MD 
By HEPP Staff
Condition Jails (%) Prisons (%)
Schizophrenia 1 2.3-3.9
Major Depression 8-15 14-18
Bipolar Disorder 1.5-2.6 2-4.3
Condition Jails
N=592,462
Prisons
N=1,210,034
% of Total US
Patients with
Indicated Condition
Asthma 44,000 96,000 9
Diabetes 12,000 32,000 5
Hypertension 84,000 98,000 18.5
Continued on page 5
Condition Number of
Annual Releases
with Infection* (%)
N  8,000,000
% Total
US Patients
with the
Indicated
Condition**
HIV 98,000-148,000 ^
(1.2-1.8)
13.1-19.3
Syphilis 558,000 (6.9) N/A^^
Chlamydia
Gonorrhea
186,000 (2.3)
77,500 (0.9)
N/A^^
N/A^^
Hepatitis C (HCV) 1.4 million (17.5) 29.3-32
Hepatitis B (HBV)
Tuberculosis
155,000 (1.9)**
12,000 (0.1)**
12.4-15
35
~
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Augustine C. Mekkam, M.D., R.Ph
Since the introduction of Protease Inhibitors (PI) into the pharmacological
arsenal against the Human Immunodeficiency Virus (HIV), both the quality
and the quantity of life for HIV infected persons has increased.  For a
patient to receive these benefits, they must be dedicated to taking any of
the combination of antiretroviral drugs that now make up the so-called
Highly Active Anti-Retroviral Treatment (HAART).  Besides the cost of
these medications, the rapid mutation rate of the virus with risks of drug
resistance is reason enough to ensure rigorous adherence to the prescrip-
tions.
In correctional facilities, the issue of adherence has often been the subject
of debate between those who advocate of Directly Observed Therapy
(DOT) and Keep On Person (KOP) medication.  In DOT, the inmate-patient
goes to the medication line for each dose of their therapy.  While under
KOP, several days (up to one month) supply is dispensed to the inmate to
take at the proper times in the privacy of their cells. In addition to the drug
resistance and cost concerns, there are also the issues of patient confi-
dentiality and self-reliance/responsibility on both sides of the debate.
Advocates of DOT often argue that health care staff has the moral respon-
sibility to ensure that all eligible inmate/patients on HAART adhere strictly
to their prescriptions. They often worry that development of resistance is a
public health issue since most of these inmates will eventually parole and
risk infecting others outside the prison. Advocates of DOT are also con-
cerned that many of the inmate/patients have limited education or compre-
hension of the consequences of poor compliance and hence must be given
extra help in order to attain the maximum benefits of HAART.  From a fis-
cal point of view, it is argued that non-compliant inmates waste expensive
medications and, as such, DOT must be instituted to prevent wasting these
medications.
The opponents of DOT advocate for KOP as the best means of delivering
HAART to inmate-patients. They argue that the complexities of HAART
regimens coupled with the side effects make it inhumane to require
inmates to visit the medication lines several times each day.  They note that
if the goal of DOT were to prevent development of drug resistance, then it
would ultimately achieve the opposite effect by discouraging inmates from
going to the medication lines.  Another argument in favor of KOP is that
patients are able to maintain their confidentiality, whereas going to "pill
lines" several times daily reveals their HIV status.  On a fiscal note, some
argue that DOT is labor intensive and costly since is requires a nursing staff
administer and note each dose of the HAART given.
Both sides of the debate have valid points and only a compromise can
bridge the differences. The need for such a compromise is what led to the
development of a Modified DOT system of HAART administration. Under
this system, HIV positive inmates on HAART go to the medication line each
morning where they are issued individually packed, one-day supplies of
each medication.  For the rest of the day, they do not have to return to the
line.  Patients self-administer the prescriptions with instructions at the
appropriate times without fear of inadvertently revealing their HIV status to
other inmates.  Under this system, medical staffs are able to identify those
inmates who are not showing up for their daily supplies of the medications.
The non-adherent inmates are counseled appropriately. One disadvantage
is the increased time the pharmacy has to spend packaging the medica-
tions.  However, this cost in pharmacy manpower may be offset by the fact
that the medication line will not need as much staffing in the afternoon and
evenings as compared to the DOT system.
Although the debate is ongoing, it is believed that Modified DOT will be per-
ceived in due course to be a positive balance which addresses patient con-
fidentiality, ensures compliance monitoring, minimizes the risks of drug
resistance.  Above all, Modified DOT makes the inmates active participants
in their care since they would not only be trusted to go to the medication
lines each morning, but would be trusted to remember to take the medi-
cines reliably.
Expert Opinion: Arguments For and Against Directly Observed Therapy for HAART
 Establish a national vaccine program to support the implemen-
tation of nationally recommended vaccination protocols in correc-
tional settings.
 Promote discussions in ethical decision making among correc-
tional and health authorities to improve their approach to ethical
challenges in corrections.
 Design and promote interventions to reduce obstructions to the
implementation of effective public health programs in correctional
facilities and the community.
 Provide incentives to prisons and jails to expand alcohol and
other drug treatment programs and make these services available
to inmates from admission through release.
 Support research in correctional health care including projects
that emphasize creative and cost-effective options for continuity
of care following release.
 Require correctional systems to adhere to nationally recognized
standards for access, quality of care, quality of service and appro-
priate credentialing.
The report is also likely to recommend that state and local correctional
agencies provide a smoke free environment, healthy diets, and vaccines
such as Hepatitis B as well as screen pregnant women for these dis-
eases. Moreover, it suggests enhanced collaborations between with state,
local, and other public health entities such as the CDC to analyze poten-
tial benefits to the community from early diagnosis of these diseases and
treatment.
According to Dr. Greifinger, this project is the first accurate projection of
the burden of illness among released inmates. "Correctional agencies
have never been charged with the job of protecting the public’s health.
What we’re saying is it should be part of their job. There should be a clear
public mandate for a correctional institution to work with inmates in terms
of the public’s health in three areas: communicable disease, mental ill-
ness and chronic disease.  I’m hoping this (report) will set a new standard
for the expectations for the medial care of inmates in correctional institu-
tions. This does not compete with current accreditation standards. It 
enhances them. We are talking about promoting new opportunities to
improve health care for inmates in areas where it will have a positive
effect on the community."
An audio tape copy of Dr Greifinger’s presentation at the NCCHC confer-
ence can be obtained from the NCCHC by calling 773-880-1460.
Spotlight:  Revealing the Need for Change: An Interview with Robert Greifinger, MD 
Continued from page 4
References:
1 Hammett TM, Harmon P, Rhodes W.  The Burden of Infectious Disease Among Inmates and Releasees from Correctional Facilities. Prepared for
the National Commission on Correctional Health Care-National Institute of Justice "Health Status of Soon-to-be-Released Inmates" Project, presented
at teh Meeting of the Expert Panel on Communicable Disease, June 14-15 1999, Chicago IL.
Figure 1. Number of Known Cases of HIV 
Among Incarcerated Men and Women by State, 1996
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Figure 2.  Infectious Disease Among 
Incarcerated Populations, 1996
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HEPPigram A feature of HEPP News providing concise solutions to correctional HIV-related problems.
Disease Among Incarcerated Populations
The following graphs show infectious disease among incarcerated populations. In 1996, there were estimated to be approximately 16,000 known
HIV infected inmates and does not include the number with undiagnosed HIV infection.  HIV prevalence among women and minorities is higher than
among men and whites, respectively, in almost every geographical location. The first is adapted from Hammett TM, and Maruschak, LM. 1996-1997
Update: HIV/AIDS, STD’s and TB in Correctional Facilities. July 1999.  NCJ 176344.  The second is taken from a report given at the Meeting of the
Expert Panel on Communicable Disease "Health of Soon-to-Be-Released Inmates" Project.  June 14-15, 1999, Chicago, IL. See the Spotlight, Table
1 for numbers.
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R E S O U R C E S
Amfar’s HIV/AIDS Treatment Directory
A new Web site provides up-to-date information on approved and
experimental HIV therapies for doctors and patients.  Located at
www.amfar.org/td, the site includes a searchable database of clinical
trials of experimental treatments.  Also on the Web site is a tool that
helps determine the programs that may be best for a patient.  
Telephone Numbers:
National Clinicians PEP Hotline:
888. 448. 4911
National HIV Telephone Consultation Service:
800. 933. 3413
Websites:
HIV/AIDS Treatment and Information Services (HIVATIS) webpage
http://www.thebody.com/hivatis/agents/agents01.html
The Bureau of Justice Statistics
http://www.ojp.usdoj.gov/bjs
JAMA HIV/AIDS Information Center
http://www.ama-assn.org/special/hiv
CDC HIV/AIDS Statistics
http://www.cdc.gov/nchstp/hib_aids/stats/hasr1001.pdf
The Corrections Connection
http://www.corrections.com
N= 98,000         148,000       558,000       186,000        77,500        1.4 million     155,000         12,521
%= 13.1               19.3             n/a               n/a             n/a               31.7             13.7              6.0
Figure 2. This figure shows the number of inmates with selected infections.  The percentages are the percent of the total US patient pop-
ulation infected with the indicated disease that passed through correctional facilities in 1996.
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UNAIDS and WHO: HIV/AIDS Cases will
Continue to Rise
On December 1, the last World AIDS Day of
this millenium, it seemed appropriate to read
the Lancet’s report on the UNAIDS and WHO
predictions for HIV/AIDS in the next century.
At the close of 1999, UNAIDS and WHO esti-
mate that 32.4 million adults and 1.2 million
children will be living with HIV/AIDS.  This
past year saw the highest global total of
deaths than any other year of the epidemic:
2.6 million children and adults died from
AIDS in 1999. (Haroon A.  Lancet. Nov 27
1999; 354: 1886.)
Peer HIV Education Programs in
Corrections
Three articles in the last issue of the Journal
of the Association of Nurses in AIDS Care
addressed recent findings concerning HIV
care and inmates. A study conducted in a
medium-to-maximum security prison in the
rural South revealed that among 57 newly
incarcerated women there is a high preva-
lence of domestic violence, three or more
sexual partners (10%) and unprotected sex
during every encounter within the previous
month (72%). Nearly all (97%) reported illicit
drug use as well as sex with an injection drug
user, yet more than half thought they had lit-
tle or no risk for HIV infection or other sexual-
ly transmitted infections. Limited prevention
programs were available for them at the time
of discharge to the community. (Fogel C,
Belyea M. J Assoc Nurses in AIDS Care.
12/99; 10(6) 66).
Another article in the the same issue advo-
cates peer education for prisoners and
asserts that nurses have a  responsibility for
assisting in the design and deployment of
such programs. An ideal peer education pro-
gram curriculum should carefully select
inmate peers after considering their prison
sentence, the type of offense committed, gen-
der and race/ethnicity.  Minimal curriculum
must incorporate a basic understanding
HIV/AIDS, issue of its origins, including con-
spiracy theory, and facilitate discussion using
commonly used vocabulary terms. (Dubik-
Unruh S. J Assoc Nurses in AIDS Care.
12/99; 10(6) 53.)
An additional article spotlights ACE, a peer
support program for female prisoners with
HIV/AIDS. The AIDS Counseling and
Education Program (ACE) helps with the cri-
sis at Bedford Hills Correctional Facility, New
York State’s maximum security prison for
women.  The ACE program educates
inmates about preventing HIV, provides sup-
portive counseling, and uses community
groups to facilitate women’s re-enter to soci-
ety.  It also encourages adherence with anti-
retroviral therapy. (Boudin K, Carrero I, Clark
J. et al. J Assoc Nurses in AIDS Care. 12/99;
10(6) 90.)
OSHA/CDC Urge the use of Safety Needles
The CDC has urged health facilities to use
specially designed safety needles to protect
health care workers (HCWs) from accidental
needle stick injuries.  The notice comes just
weeks after the Occupational Safety and
Health Administration authorized its inspec-
tors to issue citations to health care facilities
that fail to use the safer needles.  The FDA
has already approved 50 safety needles and
syringes, including those that have
retractable needles, syringes with protective
sheaths and vaccine injectors that use pres-
sure rather than a needle to deliver medica-
tion.  It is estimated that the use of safety nee-
dles would reduce the injuries by 80% among
the 600,000 annual needlestick injuries to
HCWs. Unfortunately, only 15% of hospitals
currently use safety needles.  Three states
(CA, MD, TN) currently legislate mandatory
use of safety needles and 20 others are con-
sidering similar legislation. Cost is cited as a
barrier to safety syringe use which cost to
$.25 compared to $.06 per routine needle.
(Press release, November 23, 1999. Full arti-
cle available at:
http://www.cdc.gov/od/oc/media/pressrel/r99
1123.htm). Editor’s note: OSHA’s standards
presumably apply in the correctional setting.
HIV Plus: Prison Issue
HIV Plus, the largest-circulation HIV maga-
zine in the US, has produced a special com-
prehensive issue on prisons.  HIV Plus is dis-
tributed free to AIDS service providers.  For a
single copy, fax request to 212.334.9227 or
call 212.625.0897.  For bulk orders (25+) call
212.334.9119 ext.42.  Also available at
www.aidsinfonyc.org/hivplus.
News Flashes 
SUBSCRIBE TO HEPP NEWS
FAX TO 800.671.1754 FOR ANY OF THE FOLLOWING: (please print clearly or type)
____  Yes, I would like to add/update/correct (circle one) my contact information for my complimentary subscription of HEPPNews fax newsletter.
____  Yes, I would like to sign up the following colleague to receive a complimentary subscription of HEPPNews fax newsletter.
____  Yes, I would like to order the following back issues (please include volume/issue/date).
____  Yes, I would like my HEPP News to be delivered as an attached PDF file in an e-mail (rather than have a fax).
NAME: __________________________________________________________________________________________
CHECK ONE: o  Physician o  Physician Assistant o  Nurse Practitioner o Nurse/Nurse Administrator
o  Pharmacist o  Medical Director/Administrator o  HIV Case Worker/Counselor o Other
FACILITY:________________________________________________ (Optional) # of HIV Infected Inmates: __________
ADDRESS: ________________________________________________________________________________________
CITY: ____________________________________STATE: _____________________________ZIP: ________________
FAX: ___________________PHONE: ___________________E-MAIL ADDRESS: ______________________________
SIGNATURE: ____________________________________________ DATE:____________________________________
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1 Continued from October: Part 2: Drug Interactions: Protease Inhibitors and Non-nucleoside Reverse Transcriptase InhibitorsEffect of Drug on Levels (AUCs)/Dose (Adapted from HIVATIS webpage:  www.thebody.com/hivatis/agents/agents01.html)
Drug Affected Ritonavir Saquinavir * Nelfinavir Amprenavir Nevirapine Delavirdine Efavirenz
Indinavir
(IDV)
Levels: IDV up 2-
5X
Dose: Limited
data for IDV 400
mg bid, RTV 400
mg bid, or IDV
600 mg bid RTV
200 mg bid, or
IDV 800 mg bid,
RTV 100 mg bid
Levels: IDV no
effect;
SQV up 4-7x#
Dose: higher
doses may be
antagonistic^
Levels:
IDV up 50%;
NFV up 80%
Dose: limited
data for IDV 1200
mg bid  NFV
1250 mg bid
Levels: APV up
33% (750 mg
bid)
IDV down 38%
Dose: No Data
May need to up
IDV dose
Levels: IDV down
28%
NVP no effect
Dose: Standard
Levels: IDV up
40%
Dose: IDV 600
mg q 8h
Levels: IDV down
31%
Dose: IDV
1000mg
q 8h
Ritonavir
  (RTV)
Levels: RTV no
effect;
SQV up 20x**#
Dose: Invirase or
Fortovase 400
mg bid ** RTV:
400 mg bid
Levels: RTV no
effect; NFV up
1.5x
Dose: limited
data for RTV 400
mg bid  NFV 500-
750 mg bid
No Data Levels:
RTV down 11%
NVP no effect
Dose:
Standard
Levels: RTV up
70%
Dose: No data
Levels: RTV up
18%
EFV up 21%
Dose: RTV  600
mg bid (500 mg
bid for
intolerance)
Saquinavir
  (SQV)
see under SQV
column
Levels:
SQV up 3-5x;
NFV up 18% #
Dose: Standard
NFV ; FTV 1200
tid
Levels: APV
down 32%
SQV up 20%
Dose: No Data
Levels:
SQV down 25%
NVP no effect
Dose: No Data
Levels: SQV up
5x;** DLV no
effect
Dose: Fortovase
800 mg tid, DLV
standard (monitor
transaminase
levels)
Levels: SQV
down 62%
EFV down 12%
co-administration
not
recommended
Nelfinavir
  (NFV)
See under NFV
column
See under NFV
column
Levels:  No
change in APV
NFV up 15%
Dose: standard
Levels: NFV up
10%
NVP no effect
Dose: standard
Levels: NFV up
2x
DLV down 50%
Dose: no data
(monitor for
neutropenic
complications)
Levels: NFV up
20%
Dose: Standard
Nevirapine
  (NVP)
see under NVP
column
see under NVP
column
see under NVP
column
No Data - May
reduce APV
levels
No Data No Data
Delavirdine
  (DLV)
see under DLV
column
see under DLV
column
see under DLV
column
No Data - May
increase APV
levels
No Data__ No Data     APV-
              EFV
      no data, may
  reduce APV
* Several drug interaction studies have been completed with saquinavir given as Invirase or Fortovase. Results from studies conducted with Invirase
may not be applicable to Fortovase.
** Conducted with Invirase.
# Conducted with Fortovase (FTV).
^ A test tube study published in the July issue of the Journal of Infectious Diseases showed that low doses of saquinavir and indinavir appeared to
work together to inhibit HIV replication. However, as the doses increased the two drugs appeared to work against each other, counteracting their
combined antiviral effects against the virus. The scientists involved with the study were concerned that using these two protease inhibitors together
could increase the chances of the virus developing resistance to both drugs.
Subscribe to HIV Inside
A new quarterly newsletter addressing HIV-management issues specific to correctional care.
If you are interested in receiving this free publication, please fill out the form below.  In addition to receiving HIV Inside, this con-
tact information will be entered into an HIV-management database, allowing additional education materials to be forwarded.
Name ________________________________________________________________________________________
Title ________________________________________________________________________________________
Agency/Facility ________________________________________________________________________________
Address________________________________________________________________________
City ______________________________________________ State ______________________ Zip __________
Phone ____________________________________________ Fax ______________________________________
Fax back to Brendan Maney at World Health CME at 212.481.8534
F rthcoming
data to be pre-
sented at the
Retrovirus
Conference
February 2000.
Self-Assessment Test for Continuing Medical Education Credit
Brown University School of Medicine designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians
Recognition Award.  To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each
of the questions. A minimum of 70% of the questions must be answered correctly.  This activity is eligible for CME credit through
January 31, 2000.  The estimated time for completion of this activity is one hour and there is no fee for participation in this activity.
1. Hepatitis C prevalence in corrections is what fraction of the
total US population infected with HCV?
a) 1/8 
b) 1/6
c) 1/5
d) 1/4
e) 1/3
2. According to Robert Greifinger, the most prevalent communi-
cable diseases in correctional facilities include the following.
Rank these diseases in order of prevalence in prisons.
a) Hepatitis B 
b) Hepatitis C
c) HIV 
d) sexually transmitted diseases (syphilis, gonorrhea, and
chlamydia) 
e) airborne diseases such as tuberculosis
ranking: highest __  __  __  __  __ lowest
3. Which of the following statements is false?
a) Schizophrenia is more prevalent in corrections than
bipolar disorders.
b) Overall, the presence of major psychiatric disorders is
50 percent higher in corrections populations than in the
community.
c) Prevalence of mental illness in prisons is about twice
that in jails.
4. Review the following drug combinations, and select the choice
(a to e) that is most accurate.  Which of the following antiretrovi-
ral combinations, in combination with other antiretroviral agents,
might be appropriate for use in patients with HIV infection?
I. Ritonavir 200 mg BID + Indinavir 800mg BID (4 pills
twice daily)
II. Nelfinavir 1250 mg BID + Fortovase 1200 mg BID (11
pills twice daily)
III. Fortovase 1200 mg TID + Efavirenz 600 mg QHS (21
pills per day in divided doses)
IV. Indinavir 1200 mg BID + Nelfinavir 1250 mg BID (8
pills twice daily) 
Choose from among the following:
a) Only one of the choices above is accurate. 
b) Only I and III
c) Only II and IV
d) Only three of the choices above are accurate
e) All of the above are accurate
5. Ritonavir may increase the level of multiple antivirals.  When
combined with Ritonavir, which of the following antivirals require
a dosage adjustment when give in combination with RTV? 
a) Saquinavir
b) Nelfinavir
c) Nevirapine
d) a and b
e) all of the above
6. Which of the following statements is false?
a) Peer education is a cost effective HIV prevention strat-
egy.
b) The majority of prisoners with substance abuse disor-
ders receive drug treatment within the correctional setting.
c) The majority of prisoners with HIV infection are men.
d) Hepatitis C is the most prevalent of infectious disease
within corrections.
e) Though most prison systems make preferred combina-
tion therapy available, as many as one-third do not
receive recommended combinations.
BROWN UNIVERSITY SCHOOL OF MEDICINE  OFFICE OF CONTINUING MEDICAL EDUCATION  BOX G-A2  PROVIDENCE, RI 02912
The Brown University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continu-
ing medical education activities for physicians.  This activity has been planned and implemented in accordance with the Essentials and Standards
of the ACCME.
The use of the Brown University School of Medicine name implies review of the educational format and material only.  The opinions, recommenda-
tions and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the
Brown University School of Medicine.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660
Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
main article 5  4  3  2  1   5  4  3  2  1   
secondary 5  4  3  2  1   5  4  3  2  1   
article
HEPPigram 5  4  3  2  1   5  4  3  2  1   
updates 5  4  3  2  1   5  4  3  2  1   
save the date 5  4  3  2  1   5  4  3  2  1   
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
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